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Impact of vaccine supplies and delays
on optimal control of the COVID‑19 pandemic:
mapping interventions for the Philippines
Carlo Delfin S. Estadilla1* , Joshua Uyheng2, Elvira P. de Lara‑Tuprio1, Timothy Robin Teng1,
Jay Michael R. Macalalag3 and Maria Regina Justina E. Estuar4

Abstract
Background: Around the world, controlling the COVID-19 pandemic requires national coordination of multiple inter‑
vention strategies. As vaccinations are globally introduced into the repertoire of available interventions, it is impor‑
tant to consider how changes in the local supply of vaccines, including delays in administration, may be addressed
through existing policy levers. This study aims to identify the optimal level of interventions for COVID-19 from 2021
to 2022 in the Philippines, which as a developing country is particularly vulnerable to shifting assumptions around
vaccine availability. Furthermore, we explore optimal strategies in scenarios featuring delays in vaccine administration,
expansions of vaccine supply, and limited combinations of interventions.
Methods: Embedding our work within the local policy landscape, we apply optimal control theory to the compart‑
mental model of COVID-19 used by the Philippine government’s pandemic surveillance platform and introduce four
controls: (a) precautionary measures like community quarantines, (b) detection of asymptomatic cases, (c) detection
of symptomatic cases, and (d) vaccinations. The model is fitted to local data using an L-BFGS minimization procedure.
Optimality conditions are identified using Pontryagin’s minimum principle and numerically solved using the forward–
backward sweep method.
Results: Simulation results indicate that early and effective implementation of both precautionary measures and
symptomatic case detection is vital for averting the most infections at an efficient cost, resulting in > 99% reduction
of infections compared to the no-control scenario. Expanding vaccine administration capacity to 440,000 full immu‑
nizations daily will reduce the overall cost of optimal strategy by 25%, while allowing for a faster relaxation of more
resource-intensive interventions. Furthermore, delays in vaccine administration require compensatory increases in the
remaining policy levers to maintain a minimal number of infections. For example, delaying the vaccines by 180 days (6
months) will result in an 18% increase in the cost of the optimal strategy.
Conclusion: We conclude with practical insights regarding policy priorities particularly attuned to the Philippine
context, but also applicable more broadly in similar resource-constrained settings. We emphasize three key takeaways
of (a) sustaining efficient case detection, isolation, and treatment strategies; (b) expanding not only vaccine supply
but also the capacity to administer them, and; (c) timeliness and consistency in adopting policy measures.
Keywords: Optimal control, COVID-19 pandemic, Philippines, Non-pharmaceutical interventions, Vaccines
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Background
In the year since the emergence of the global coronavirus
disease 2019 (COVID-19) pandemic, national policies
have had to decisively manage diverse issues of resource
availability, institutional capacity, and collective behavioral change [1–3]. Striking the right balance of multiple
strategies at the right time has been vital for implementing successful pandemic responses [4, 5]. Mathematical
modelling has helped scientists and policymakers incorporate emergent discoveries about COVID-19 with existing knowledge to design effective interventions [6, 7].
In early 2021, the global introduction of vaccination as
a viable counter to the disease prompts new analytical
efforts. Regional inequalities introduce challenges to the
global vaccine supply chain which may disrupt a straightforward vaccine rollout for a significant proportion of
various national populations [8, 9]. Important questions
emerge with respect to how governments may adequately
adjust existing policies available for pandemic control in
relation to multiple scenarios.
This paper undertakes an optimal control study of
policies to control the COVID-19 outbreak in the Philippines, a developing country that may be particularly
vulnerable to experiencing challenges to vaccine rollouts.
Amidst large-scale preparations for the evaluation, selection, and distribution of vaccines, ongoing policies to
respond to the pandemic continue to inform the Philippine government’s strategies for pandemic management
[10]. Questions around their optimal implementation
are particularly salient for developing countries that face
heavier burdens from both the pandemic and overly
restrictive quarantine measures [11]. This study therefore
asks: How should the Philippine government implement
existing strategies of community quarantine and case
detection in conjunction with the introduction of vaccine
rollouts?
Related work
Mathematical modelling for forecasting COVID‑19
outbreaks

Since the beginning of the COVID-19 pandemic, the
academic literature has witnessed a vast surge of modelling studies. Existing reviews highlight the importance
of compartmental models of COVID-19, in connection
with other models based on time series forecasting and
machine learning [12, 13]. Compartmental models mathematically encode known and emerging information
about the transmission dynamics of the disease and have
been locally applied across numerous contexts around
the world, including major sites of COVID-19 transmission like China, India, Brazil, the United States, and the
United Kingdom [14–18].
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Mathematical modelling efforts have been beneficial
for forecasting and intervention assessment [19–21].
For instance, in the United Kingdom, a stochastic, agestructured transmission model was used to quantify the
costs and mortalities of unmitigated outbreaks without
interventions, highlighting the need for sustaining combined control efforts [22]. In another example, an agestructured model with social contact matrices was used
to compare the impacts of different reopening strategies
on the relative reduction of cases in different regions in
China [23].
Optimal control theory for modelling pandemic response

In this work, we utilize optimal control theory to model
effective pandemic response. Optimal control theory
refers to a field of study that deals with finding optimal
solutions to a problem expressed in the form of a nonlinear dynamical system [24, 25]. This helps identify efficient methods of achieving desired outcomes, such as
cost-effective infection control [15, 26].
Numerous studies have implemented optimal control
theory toward similar end goals. In the absence of vaccines, most early studies focused on non-pharmaceutical interventions, including various combinations of
rapid testing, contact tracing, and awareness campaigns
[27–31]. Ullah and colleagues sought to disentangle
the impacts of quarantine and case detection rates on
exposed, critical, and hospitalized COVID-19 patients
[32]. Other research modelled the effect of limited total
testing resources, through the addition of an isoperimetric constraint to the optimal control problem [33].
Eventually, however, newer research was further able
to consider the impacts of eventual vaccine availability.
In an age-structured model, Bonnans and Gianatti studied minimization of the death toll, cost of confinement,
and hospitalization peaks discussing a possible extension
of their model when a vaccine becomes available [34].
Libotte and colleagues likewise explored programs for
vaccine administration within a multi-objective setup,
determining a set of Pareto optimal strategies that would
minimize infections while also minimizing the number of
vaccines needed [35].
Responding to COVID‑19 in the Philippines

The present work specifically investigates the dynamics
of COVID-19 in the Philippines and aims to identify optimal strategies for efficiently controlling infections. We
draw on existing modelling efforts by the national pandemic surveillance system [36] to derive realistic parameters which match existing epidemic trends and available
intervention strategies in the country [37]. By deploying
models informed by local parameters of the disease, we
therefore aim to provide both theoretically optimal and
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contextually practical recommendations for policymakers [38].
In the Philippines, non-pharmaceutical interventions
have primarily included phased community quarantines
and mandated wearing of face masks [39]. Enhancements
to the capacity of the health system to efficiently detect
asymptomatic and symptomatic infectious individuals have also been key [40, 41]. In early 2021, imminent
vaccine rollouts posed a salient new factor for pandemic
control. We therefore sought to design optimal strategies
for their distribution, and consider appropriate responses
to potential obstacles which may arise in resource-constrained settings.
Aims of the current study

Burgeoning scholarship points to rich global knowledge
of the effectiveness and efficiency of various policy tools
against the pandemic. However, both nationally specific
impacts of the pandemic and the limitations faced by
intervening bodies highlight the importance of grounding optimal control analysis in the local context.
In this view, the present work therefore aims to achieve
the following goals. First, we frame pandemic interventions with vaccinations as an optimal control problem to
identify scenarios for effective pandemic control. Second,
we explore various vaccination scenarios featuring both
delays and expansions of vaccine administration. This
enables a future-oriented analysis of how local policymakers may compensate for unforeseen developments in
the global supply chain. Finally, we perform a systematic
ablation analysis, whereby we restrict various combinations of available controls to model more limited control
scenarios.
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Methods
Model formulation

To capture the local dynamics of COVID-19 transmission
in the country, we form a model that utilizes the local
incidence data from the Department of Health-Epidemiology Bureau (DOH-EB) [42]. The COVID-19 model
utilizes six compartments to subdivide the population:
susceptible (S), exposed (E), infectious but asymptomatic
(Ia ), infectious and symptomatic (Is ), confirmed (C), and
removed (R). These compartments are governed by the
epidemic flow as illustrated in Fig. 1. Compartment S
consists of individuals who have not been infected with
COVID-19 but may contract the disease once exposed
to the virus. Compartment E consists of individuals who
have been infected but are still within the latency stage
of the disease. These individuals will eventually become
infectious, and categorized into two compartments
depending on the presence ( Is) or absence ( Ia) of symptoms. Once detected, these infectious individuals will
move to compartment C, where they will be included
among the active cases. Individuals in this compartment
are assumed to be isolated, and hence not capable of
infecting the susceptible population, and receiving treatment while in isolation. Lastly, compartment R consists
of individuals who have acquired immunity from the disease. We assume that those who have recovered from the
disease acquire permanent immunity and therefore move
to compartment R.
The movements of individuals toward and out of the
different compartments are governed by several parameters of the model. The transmission rate β is a function
of the disease transmission rate β0, based on an assumed
basic reproduction number R0, and a reduction factor
(1 − ). The parameter  reflects the effect of community

Fig. 1 Diagram of the compartmental model. Disease progression from the susceptible (S) compartment through the exposed (E), asymptomatic
(Ia ) and symptomatic (Is ) infectious, confirmed (C), and removed (R) compartments
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quarantine imposed by the government, as well as the
degree of compliance to minimum health standards,
which includes practicing proper hygiene, social distancing, and wearing protective face coverings. Moreover, the
parameter ψ accounts for the infectiousness of asymptomatic individuals relative to those who have symptoms.
The rates of transfer to the two infectious compartments,
αa for asymptomatic and αs for symptomatic, are both
dependent on the incubation period τ of the virus.
Other parameters in the model include the constant
recruitment rate A into the S compartment, which is
driven by new births in the population. To account for
deaths by natural causes, a constant rate of µ per unit
time is applied to all compartments in the model. In addition, deaths due to the disease are included through the
parameters ǫI and ǫT , affecting the infectious symptomatic and confirmed compartments, respectively.
By taking into account the above assumptions, a mathematical model is developed, which can be described
by the following system of six ordinary differential
equations:

dS
ψIa + Is


= A − βS
− µS, S(0) ≥ 0,


dt
N



+
I
ψI
dE
a
s


= βS
− (αa + αs + µ)E, E(0) ≥ 0,


dt
N



dI

 a = αa E − (µ + ω + δa + θ)Ia , Ia (0) ≥ 0,
dt
dIs


= αs E + ωIa − (µ + ǫI + δs )Is , Is (0) ≥ 0,



dt


dC


= δa Ia + δs Is − (µ + ǫT + r)C, C(0) ≥ 0,



dt


dR


= θ Ia + rC − µR, R(0) ≥ 0,
dt
(1)
c
1−c
β = β0 (1 − ),
αa = τ ,
αs = τ ,
where
N = S + E + Ia + Is + C + R. The functions S, E, Ia, Is,
C, and R are differentiable real-valued functions on R.
Moreover, all parameters are nonnegative constants.
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Organization [47, 48]. The proportion of asymptomatic
cases (c) is from Mizumoto et al. [49] that studied the
COVID-19 outbreak at the Diamond Princess cruise ship.
We fit the model output to data by employing a curvefitting algorithm to estimate the value of the transmission
reduction rate (), the initial values for the exposed (E(0)),
infectious asymptomatic ( Ia (0)), and infectious symptomatic ( Is (0)). In particular, the constrained L-BFGS optimization procedure [50] was utilized to minimize the
sum of squared errors between the model output and the
empirical time series. The parameter  is fitted on a permonth basis starting from March 2020, to coincide with
the changes in the disease dynamics and the corresponding transmission reduction policies implemented by
the government that tends to be updated monthly [51].
The output is a vector of best-fit transmission reduction parameters [1 , 2 , ..., n ] where n is the number of
months since March 2020. This fitting procedure is utilized to produce forecasts for the Philippine COVID-19
epidemic [36]. Following the above parametrization, our
model fits well to the Philippine data for cumulative cases
of COVID-19 (Fig. 2). Table 1 summarizes the parameter
values used in the model.
Model with optimal control

We explore four control strategies to mitigate the
COVID-19 epidemic-precautionary measures, detection
of asymptomatic cases, detection of symptomatic cases,
and vaccination. The definitions of each of these controls
and how they are incorporated in the model are given
below:
1. Precautionary measures (u1 (t)) refer to governmentled efforts to inhibit possible contacts between susceptible and infectious individuals by regulating
public gatherings, closing schools, suspending office
work, enforcing adherence to health protocols such
as social distancing, mask-wearing, hand-washing,

Parameter values

The values of various parameters were determined using
several sources and methods. Local COVID-19 data [42]
were used in calculating detection rate (δa , δs), postdetection recovery rate (r), and death rate of COVID-19
cases (ǫI , ǫT ). The recruitment rate (A) and natural death
rate (µ) are calculated from population data [43–45]. For
the other parameters which cannot be computed directly
from data, we rely on references that estimate their values. The basic reproduction number of COVID-19 ( R0)
and relative infectiousness of asymptomatic cases (ψ ) are
based on estimates by the US Centers for Disease Control [46]. The incubation rate (τ ) and symptomatic transition (ω ) are obtained from reports by the World Health

Fig. 2 Fit of model output to data following L-BFGS optimization
procedure
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Table 1 Summary of parameter values for the COVID-19 model
Variable

Description

Value

Unit

Source

R0

Basic reproduction number

4.0000

None

[46]

A

Recruitment rate

1309.1

1/day

[43, 45]

µ

Natural death rate

4.0548 × 10−5

1/day

[44]

β0

Baseline transmission rate

0.4343

1/day

[46]



Transmission reduction

0.6500 to 0.8500

1/day

[36]

ψ

Relative infectiousness of asymptomatic cases

1.0000

None

[46]

τ

Incubation period

5.0000

Day

[48]

c

Proportion of asymptomatic infections

0.1800

None

[49]

ω

Symptomatic transition

0.3300

1/day

[47, 49]

θ

Recovery rate of asymptomatic

0.0714

1/day

[42]

δa

Detection rate for asymptomatic

0.1000 to 0.2000

1/day

[42]

δs

Detection rate for symptomatic

0.1000 to 0.2000

1/day

[42]

r

Post-detection recovery rate

0.0855

1/day

[42, 48]

ǫI

COVID-19 death rate, undetected

0.0018

1/day

[42]

ǫT

COVID-19 death rate, detected

0.0018

1/day

[42]

etc. This control affects the transmission rate β and
is incorporated in the model as a factor (1 − u1 (t)),
replacing (1 − ). The value of u1 (t) represents the
effort of precaution at time t. A value of 0 indicates
that no precautionary measure is being practiced,
and a value of 1 indicates full effort on precaution
prohibiting any form of infection.
2. Detection of asymptomatic cases (u2 (t)) entails identifying and isolating infectious individuals who do
not have symptoms of COVID-19. This may be done
through laboratory tests such as reverse transcription-polymerase chain reaction (RT-PCR) to determine whether an individual is infectious or not. A
positive case is taken to be immediately followed by
isolation at home or in a dedicated quarantine facility
to prevent transmission. It is assumed, therefore, that
after an individual is confirmed to have COVID-19,
s/he is not able to infect susceptible individuals. We
incorporate this control to the model by replacing δa
with a time-varying control function u2 (t). The value
of u2 (t) represents the effort of testing and isolation
at a given time t. A value of 0 indicates the absence of
testing and isolating, and a value of 1 indicates testing and isolating all infectious asymptomatic individuals on a given unit of time.
3. Detection of symptomatic cases (u3 (t)) follows the
same definition as the detection of asymptomatic
cases but applied to individuals that exhibit symptoms of COVID-19. We replace δs by u3 (t) to incorporate this control to the model. Similarly, a value of
0 of this control indicates the absence of effort to test
and isolate symptomatic individuals while a value of

1 indicates full testing and detection of all symptomatic individuals on a given unit of time.
4. Vaccination (u4 (t)) refers to the full inoculation of
susceptible individuals for them to acquire protection
against COVID-19 infection or protection against a
severe case of the disease. We assume in this paper
that vaccines give protection against infection, that
is, an individual who is fully vaccinated gets immunity to COVID-19 over the period considered. Multiple vaccines with varying effectiveness rates have
been identified for use against COVID-19 such as
those developed and manufactured by Pfizer-BioNTech, Moderna, Sinovac, etc. We consider the average effectiveness rate of the vaccines weighted by the
usage, denoted by σ , where 0 ≤ σ ≤ 1. To incorporate vaccination in the model, we add a rate of transfer from compartment S to R equal to σ u4 (t). The
value of u4 (t) represents the effort of vaccination for
the susceptible population. A value of 0 represents no
vaccination efforts while a value of 1 represents vaccination of all susceptible individuals on a single unit
of time.
Our goal is to identify the optimal strategy for limiting
the spread of SARS-CoV-2 in a population using minimal
cost of controls. In this study, the optimal control problem minimizes the number of asymptomatic ( Ia) and
symptomatic individuals ( Is) and the control costs. The
controls are expressed in quadratic forms to incorporate
nonlinear costs for the implementation of each control
and to ensure the convexity of the cost function. This
is a common form of an objective functional in optimal
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control problems [25, 52]. The objective functional is rep- The state variables are solved forward in time while the
adjoint variables are solved backwards, referred to as
resented by:

 tf 
(2)
Ia (t) + Is (t) + w1 u21 (t) + w2 u22 (t) + w3 u23 (t) + w4 u24 (t) dt,
J (�
u) =
t0

where t0 and tf represent January 1, 2021 and December 31, 2022 respectively, reflecting a 2-year period. The
parameters wi , i = 1, 2, 3, 4, account for the relative costs
of implementing controls ui . They represent the weights
of corresponding terms in the integrand and their importance in the optimal control problem.
We aim to identify u∗i (t), i = 1, 2, 3, 4, such that


J u∗1 , u∗2 , u∗3 , u∗4 = min J (u1 , u2 , u3 , u4 ),
(3)
U
where for Lebesgue integrable ui,


, t0 ≤ t ≤ tf .
U = (u1 , u2 , u3 , u4 )|umin
≤ ui (t) ≤ umax
i
i

Here, umin
and umax
are the lower and upper bounds of
i
i
the control ui , representing minimum and maximum
implementation efforts.
The constraints of the optimal control problem are
given by:


































dS
ψIa + Is
= A − (β0 (1 − u1 ))S
− σ u4 S − µS, S(0) ≥ 0,
dt
N
ψIa + Is
dE
= β0 (1 − u1 )S
− (αa + αs + µ)E, E(0) ≥ 0,
dt
N
dIa
= αa E − (µ + ω + u2 + θ)Ia , Ia (0) ≥ 0,
dt
dIs
= αs E + ωIa − (µ + ǫI + u3 )Is , Is (0) ≥ 0,
dt
dC
= u2 Ia + u3 Is − (µ + ǫT + r)C, C(0) ≥ 0,
dt
dR
= θIa + rC + σ u4 S − µR, R(0) ≥ 0,
dt

where

(4)

N = S + E + Ia + Is + C + R.
The existence of the optimal solution can be shown using
standard results in optimal control theory [25, 52]. The
necessary convexity of the integrand of the objective
functional, positive definiteness of system (4), and the
linear dependence of the state differential equations to
the controls are satisfied in our model.
We apply Pontryagin’s minimum principle [24] to
determine the necessary conditions using the optimality
system for our problem (see Additional file 1: Appendix).
This system is a two-point boundary problem with initial conditions for the state variables and terminal conditions for the adjoint variables. The solutions are solved
numerically using a Runge–Kutta fourth-order scheme.

max ) bounds for control
Table 2 Lower (umin
i ) and upper (ui
strategies representing available effort in the Philippines

Control

umin
i

umax
i

Sources
[36]

Precaution (u1)

0

0.850

Detection of asymptomatic (u2)

0

0.200

[42]

Detection of symptomatic (u3)

0

0.200

[42]

Vaccination (u4)

0

0.002

[10]

Forward–Backward Sweep Method [25]. We update the
controls using a convex combination of the latest and
previous values. This process is iterated until the updates
in the control values are very small or less than the
machine epsilon.
The initial state values are computed using a combination of data and model fitting. We relied on model
fitting to data to get the values for E(0), Ia (0) and Is (0)
[36]. The initial value for confirmed cases (C(0)) is based
on data from the Department of Health [42]. The initial
number of removed individuals (R(0)) is assumed to be
higher than the detected recoveries on January 1, 2021, to
include recoveries from undetected asymptomatic cases.
We estimate that this is equal to 450,000, consistent with
the output of our model [36]. Lastly, the initial susceptible population is estimated to be equal to the whole
population minus the assumed values for the other compartments. Table 3 lists the initial state values used in our
simulations.
= 0 for i ∈ {1, 2, 3, 4} while upper bounds
We fix umin
i
of the controls are varied to reflect the realistic maximum
efforts that can be achieved with each control. Results
from model fitting to data (see Table 1) show that the
highest value for precaution is 0.85. Direct computations
from epidemiological data provided by the Department
of Health [42] show that the minimum monthly average
Table 3 Initial values for model states
State

Initial value

Susceptible (S)

108,960,983

[45]

7000

[36]

Infectious asymptomatic (Ia)

500

[36]

Infectious symptomatic (Is)

9000

[36]

57,833

[42]

Exposed (E)

Confirmed cases (C)
Removed (R)

450,000

Sources

[36, 42]
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Limited information is available as of writing to
estimate the vaccine effectiveness parameter (σ ) for
COVID-19. Moreover, various vaccines with different
effectiveness rates will be deployed in the Philippines as
they become available [10], making it more difficult to
give a realistic estimate of this parameter. The best alternative is to equate this to the pooled effectiveness of vaccines for a similar disease such as influenza, which is at
σ = 0.7 [53].

duration of detection, from symptom onset to confirmation of test results, may take 5 days. We take the inverse
of this duration as our upper bound for both detection
= umax
= 0.2. Lastly, the upper
controls, hence umax
2
3
bound for vaccination (u4 ) is based on government proclamations [10]. The boundaries for the control values are
summarized in Table 2.
The weight parameters wi , i = 1, 2, 3, 4, are adjusted
to balance the terms in the integrand of the cost function (2). These parameters reflect the total costs and
payoffs of implementing each control strategy including
the cost of the products used (test kits, vaccines, masks,
etc.), operational costs (personnel salary, rent, procurement, refrigeration units, etc.), opportunity costs for the
economy due to lockdowns, and so forth. To determine
the values of the weight parameters, we consider the fact
that the upper bounds for the controls already reflect
the realistic and achievable efforts that the Philippine
government can exert, given the historical and prospective cost and availability of each control. Recall that the
upper bounds for precaution, detection of asymptomatic
cases, and detection of symptomatic cases are based on
data, and the upper bound for the vaccination control is
based on government targets. Based on this, we assume
that a lower umax
signifies a relatively higher implemeni
tation cost for the i-th control as implementing the control beyond this upper bound is not readily available to
the government. Given this, we rescale the terms in the
cost function (2) by equating the weight parameters to
the inverse of the maximum allowable effort for each
control (w1 = 1/0.85, w2 = w3 = 1/0.2, w4 = 1/0.002).
This improves the balance of the terms in the cost function and reduces the bias to implement controls that have
lower upper bounds.

Results
Optimal control strategies for COVID‑19 in the Philippines

Solving the stated optimal control problem in Eqs. 2–4
generates the optimal levels of precaution (u1), asymptomatic detection (u2), symptomatic detection (u3),
and vaccination (u4 ) over the 2-year period from January 1, 2021 to December 31, 2022 (Fig. 3). Notably, the
maximum feasible vaccination rate must be sustained
throughout the entire 2-year period. Symptomatic detection must likewise maintain a high value close to the
maximum feasible value, lowering slightly in the first 6
months of 2021. Asymptomatic detection and precaution must likewise be implemented at their maximum
respective values early in 2021. But asymptomatic detection may be eased to nearly zero by the second quarter of
2021, while precaution eases a bit by the second half of
2021, then is gradually reduced throughout the remainder of the 2 years under consideration.
We also simulate a no-control scenario by setting the
controls to 0 throughout the 2-year period. A dramatic
difference is observed between the with-control and
without-control conditions (Fig. 4). Without controls,
a peak number of 100 million infectious individuals is
achieved within the first quarter of 2021. Meanwhile,

Level of Intervention

Precaution (u1)

Detection of Asymptomatic (u2)

0.8

0.20

0.6

0.15

0.4

0.10

0.2

0.05

0.0
2021−01 2021−07 2022−01 2022−07 2023−01

0.00
2021−01 2021−07 2022−01 2022−07 2023−01

0.20

Detection of Symptomatic (u3)

0.0020

0.15

0.0015

0.10

0.0010

0.05

0.0005

Vaccination (u4)

0.0000
0.00
2021−01 2021−07 2022−01 2022−07 2023−01
2021−01 2021−07 2022−01 2022−07 2023−01

Date
Fig. 3 Optimal control strategy for the COVID-19 epidemic in the Philippines

Infectious Asymptomatic and Symptomatic
(Ia+Is)
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Policy impacts of vaccine delays

With the bottleneck in the global supply of vaccines, it is
of chief concern when a country can start vaccinating its
population. It is not far-fetched for countries to experience delays in vaccination which in turn, would have an
effect on policy. Here, we look into the impact of vaccine
delay on the optimal control strategy. To achieve this,
we add the following constraint to the optimal control
problem 2–4:

7 500

5 000

2 500

u4 (t) = 0,

0
2021−01 2021−07 2022−01 2022−07 2023−01

Date

Fig. 4 Total infectious individuals (Ia + Is) with full implementation of
the optimal control strategy

with the optimal implementation of all controls, the total
number of running infections is driven down quickly
in early 2021, without ever breaching the 10,000-mark.
After the full-throttle implementation of all controls in
early 2021, sustained efforts at detecting symptomatic
individuals and proactively vaccinating susceptible populations may thus be sufficient to prevent the infected
population from rising. So long as the latter strategies are
maintained, the majority of the population may slowly
ease stringent distancing rules and fewer resources need
to be urgently allocated to asymptomatic detection.

u1

Level of Intervention

0.8

0.20

0.6

0.15

0.4

0.10

0.2

0.05

t ∈ [t0 , td ],

t0 ≤ td ≤ tf ,

where td is the vaccine delay in days. We first solve for the
optimal control profiles given vaccine delays of 180, 360,
and 540 days (Fig. 5). Results reveal that increased efforts
on the other controls become necessary given longer
delays in vaccination. Primarily, precautionary measures
should compensate when vaccines are delayed. Detection of symptomatic infectious individuals should also be
strengthened for mitigation if vaccine rollout is slowed
down.
To further evaluate the effect of vaccine delay, we compute the cost of the optimal strategy in each scenario. The
cost of the control strategy (C) is defined as the integral
of the last four terms in the cost function of the optimal
control problem over the time period, specifically:
C =



tf

t0



0.0015

0.10

0.0010

0.05

0.0005

dt.

(5)
We observe that the optimal strategy in the no-delay scenario has the least cost and will also result in the least
number of total infections. Given this, we decided to

u2

Delay
0.0
0.00
2021−01 2021−07 2022−01 2022−07 2023−01
2021−01 2021−07 2022−01 2022−07 2023−01
0days
180days
u3
u4
360days
0.0020
0.20
540days
0.15



w1 u21 (t) + w2 u22 (t) + w3 u23 (t) + w4 u24 (t)

0.0000
0.00
2021−01 2021−07 2022−01 2022−07 2023−01
2021−01 2021−07 2022−01 2022−07 2023−01

Time

Fig. 5 Delay of vaccine availability increases effort for other controls in the optimal strategy. u1-Precautionary measures, u2-detection of
asymptomatic cases, u3-detection of symptomatic cases, u4-vaccination
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compare the cost of the optimal strategy in the scenarios with vaccine delay relative to the no-delay scenario.
Specifically, given vaccine delays of 30k days, where
k ∈ {0, 1, 2, 3, ..., 24}, we examine the resulting relative
cost and total infections of the optimal control strategy
(Fig. 6).
Based on our simulations, longer delays in vaccination
result in higher relative costs of the optimal strategy. For
example, delaying the vaccines by 180 days will result in
an 18% increase in cost, and delaying the vaccine by 360
days will increase the cost by 32%, due to the compensation of the other controls. We also observe that delaying the vaccine by 60 days or more will only increase the
total infections in the optimal strategy by a relatively
small amount (< 1000 additional infections). These two
findings suggest that while the number of infections can
still be effectively managed when vaccines are delayed,
vaccine delay may pose more deleterious effects on the
economy than on the overall health status of the population, even if the optimal strategy is implemented and new
cases are minimized.
Policy impacts of expanding vaccine supply

Recall that the upper bound for the vaccination control
(umax
4 ) was fixed based on the vaccination plan by the
local government. Note however that the actual vaccine
capacity is unknown and is dependent on negotiations
and supply. Here, we want to look into whether increasing vaccine supply will have a significant effect on the
optimal control strategy. To discern this relationship, we
modify the value of umax
to double and triple the initial
4

value. The value of the weight parameter w4 is equal to
1/umax
in each scenario.
4
We solve for the optimal control profiles and the result= 0.002, 0.004 or
ing number of vaccinations if umax
4
0.006 (Figs. 7, 8). We observe that increasing the vaccine
capacity will have a significant impact on the optimal
control strategy. For the three scenarios considered, the
maximum vaccination effort must be utilized for almost
the entire period, but vaccination effort is eased earlier
if the vaccine capacity is larger. Another important consequence of increasing vaccine capacity is the earlier
relaxation of the other controls, mainly precautionary
measures and detection of symptomatic cases.
Comparing the relative cost and the resulting total
infections reveals that increasing the vaccine capacity by
double or triple the initial amount will reduce the cost
of the optimal strategy (Table 4). We observe a 25% cost
reduction when vaccine supply is doubled, and 37% cost
reduction when vaccine supply is tripled, coupled with
a slight reduction in the total number of infections. This
reinforces the proposition that dedicating more resources
to vaccinations is more favorable in the long run owing to
the reduced efforts necessary for implementing the other
interventions.
Managing cost and impacts of pandemic control strategies

Finally, to integratively consider the dynamics of all
interventions, we analyzed the results of a control setup
featuring all interventions in conjunction with ablated
control scenarios featuring various subsets of the proposed controls. We compared outcomes for optimized
single control, dual control, and triple control strategies

1.4

1.3

Total Infections

Relative Cost

76 600

1.2

76 400

76 200

1.1

76 000

1.0
0

200

400

Delay (Days)

600

0

200

400

600

Delay (Days)

Fig. 6 Effects of delays in initiation of vaccination strategies on the relative cost of overall strategy (left) and resulting total infections over the 2-year
period (right)
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u1

u2
0.20

0.8

0.15

Level of Intervention

0.6
0.4

0.10

0.2

0.05

0.0
2021−01

2021−07

2022−01

2022−07

0.00
2023−01 2021−01

2021−07

2022−01

u3

2022−07

2023−01

2022−07

2023−01

u4

0.20

0.006

0.15

0.004

0.10
0.002

0.05
0.00
2021−01

2021−07

2022−01

2022−07

0.000
2023−01 2021−01

Date

Maximum Vaccination Rate

2021−07

2022−01

0.004

0.006

0.002

Fig. 7 Increasing the upper bound for vaccination control may allow for shorter and lighter precautionary measures and testing. u1-Precautionary
measures, u2-detection of asymptomatic cases, u3-detection of symptomatic cases, u4-vaccination

to simulate scenarios when the other controls are not
available, as well as to shed light on their contributions to
controlling the epidemic, and highlight the significance
of implementing all four in concert. To do this, controls

that are not being implemented in each scenario are fixed
at 0. Full details on various control profiles are available
in Additional file 1: Appendix.

Vaccinated Population

Cumulative Vaccinations

Daily Vaccinations

150 000 000

600 000

100 000 000

400 000

50 000 000
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0
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2021−01 2021−07 2022−01 2022−07 2023−01
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Maximum Vaccination Rate
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Fig. 8 The optimal number of complete vaccinations (daily and cumulative) for different values of upper bound for vaccination
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Table 4 Total infections and relative cost for optimal control
strategy when upper bound for vaccination (umax
4 ) is increased
Relative cost

umax
4

Total infections

0.002

1.0000

75,997

0.004

0.7517

75,306

0.006

0.6303

74,653

We compare all possible combinations of the controls
in terms of both their cost and the infections averted
relative to the no-control scenario (Fig. 9). Intuitively,
an ideal scenario entails low cost and high infections
averted. Strikingly, the control scenarios appear to cluster
into three major categories. First are low cost, low impact
strategies, which do not entail high costs, but also do not
effectively curb infections. These correspond to intervention programs that do not mobilize sufficient resources to
High Cost, Low Impact
u1 u2 u4
u1 u2

Cost

750

500

Medium Cost, High Impact
u1 u2 u3

u1 only
u1 u4

u1 u3

Low Cost, Low Impact

250

u2 u4
u4 only

0
0

all

u2 u3

u2 only

u3 only

u2 u3 u4

u1 u3 u4

u3 u4

30 000 000

60 000 000

90 000 000

Infections Averted by Control Strategy

Fig. 9 A menu of control strategies visualized according to
infections averted (x-coordinate) and cost (y-coordinate). Points
are sized by infections averted, such that larger points symbolize
control strategies that avert more infections. Points are also colored
by cost, such that bluer points incur lower costs, and redder
points incur higher costs. u1-Precautionary measures, u2-detection
of asymptomatic cases, u3-detection of symptomatic cases, u4
-vaccination

address the health crisis and subsequently do not achieve
the desired impact. We observe here that this cluster of
intervention combinations primarily exclude precautionary measures like community quarantines, meaning various scenarios implementing only vaccinations and case
detection strategies. This entails that, even if these strategies might be less costly-especially from an economic
perspective-than prolonged lockdowns, they may not be
sufficient on their own to control outbreak trajectories.
Especially in the early months of 2021, it will be vital for
local governments to limit unnecessary contact between
individuals, and enforce such procedures reliably and

consistently. Otherwise, even maximally implemented
case detection and vaccination strategies will not be able
to protect a significant proportion of the population from
infection.
The second category represents the worst-case scenario: high cost, low impact strategies. These indicate
attempts by governing entities to invest resources in
public health interventions, which ultimately still do not
effectively control outbreaks. This therefore presents a
severe misuse of resources without achieving desired
outcomes. Note here that these intervention combinations primarily exclude efficient detection of symptomatic cases. This means that without efficient detection
of symptomatic cases—even at full implementation of
precautionary quarantine measures, vaccinations, and
overall high costs to the economy at large-few infections
will be averted.
The final category represents the most favorable category of interventions. Here, medium cost, high impact
strategies pertain to scenarios involving some investment
of resources, directed towards the most efficient policy
levers. This results in an effective minimization of infections, thereby constituting well-targeted policy decisions
that achieve the objective of controlling the pandemic.
Now we see that both precautionary measures and efficient symptomatic case detection are vital to achieving
this set of outcomes. Even if these interventions do introduce higher costs, they can effectively quell outbreak
trajectories early on. Moreover, in these setups, their
implementation is even given an allowance for relaxation
over time if executed effectively and consistently in the
early months. This therefore reduces costs from a broader
perspective, as overall fewer infections arise nationally,
and fewer resources are demanded to address them.

Discussion
In this study, we studied optimal strategies for controlling
the spread of COVID-19 in the Philippines. We considered existing policy interventions as well as the introduction of vaccination rollouts to quell outbreak trajectories.
Dramatic differences were detected in simulated infections depending on which controls were prioritized. In
particular, we observed the importance of early and effective implementation of precautionary measures like community quarantines, coupled with efficient detection of
symptomatic cases. Furthermore, we found that even if
vaccinations alone do not constitute an efficient response
to the pandemic, expanding vaccine supply relaxes the
need for these more resource-intensive interventions.
Meanwhile, although less than ideal, delays in vaccine
administration may also be compensated through the
remaining policy levers.
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These insights bear particular consequences for policies in developing countries like the Philippines [1, 2].
Here, we highlight three key takeaways. First, more than
a year into the pandemic, it remains crucial to sustain
efficient case detection, isolation, and treatment strategies, particularly for symptomatic cases. In the Philippines, where long-term states of community lockdown
have prevailed as the government’s response to shortterm fluctuations in COVID-19 cases [39], our findings
suggest that an optimal, cost-effective strategy would
actually entail relaxations to such measures—but only
under the condition that symptomatic case detection is
properly implemented. Hence, improving the capacity
of the local health system to identify, process, and manage these cases efficiently should be a top priority beyond
cyclically adjusting quarantine levels [54].
Second, policymakers need to consider how to expand
not just vaccine supply, but also the capacity to administer them. This includes both logistical concerns regarding the strategic use of facilities to vaccinate individuals,
inform the public regarding vaccine availability and eligibility, as well as reducing vaccine hesitancy through
culturally sensitive health promotion programs that
strengthen public trust [3, 55, 56]. Only when such health
communication objectives are accomplished and collective behavioral change is initiated can the vaccination
strategies posited in this work be made feasible. Otherwise, even procuring sufficient supplies of vaccines will
not achieve its intended effects to stop local outbreaks.
Initial efforts along these lines are underway by the Philippine National Vaccine Operations Center, for which
our model results strongly reaffirm the urgency.
Third, timeliness and consistency must be emphasized
in adopting policy measures [4, 5]. Across all favorable
scenarios simulated, high levels of key interventions were
needed in the early months of 2021, with relaxations projected only mid-2021 or in 2022. Systems for detecting
existing cases, while preventing new ones, are needed for
vaccinations to meaningfully impact outbreak trajectories and reduce overall costs—especially as these systems
need to be robustly sustained in the event of potential
delays in acquiring sufficient vaccines for the entire population. This ensures that even if developing countries like
the Philippines do not hold sway over the global supply
chain of vaccines, the pandemic may still be kept under
control through means over which local policymakers do
wield authority.
It is worth noting that the conclusions of this work rest
on several assumptions. These assumptions constrain the
interpretation of our findings but likewise point to promising avenues for future work [6, 7]. A number of limitations pertain to the realism of our model. For instance,
we assume a total population that is unaffected by
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immigration and emigration flows. This can be a source
of confounding given that, despite additional precautions in travel protocols, relevant susceptible, exposed,
and infectious populations, in reality, include individuals
who may leave or arrive within national borders. Furthermore, ordinary differential equation models of diseases,
such as the one utilized in this paper, assume homogeneous mixing of individuals in the population. That is, our
model assumes that a susceptible individual has a uniform chance of being infected by any infectious individual, regardless of their geographic proximity. However, in
an archipelago such as the Philippines, this assumption
of free-mixing does not necessarily hold due to different
patterns of movement within the country and the tendency of the outbreaks to be concentrated within more
urban areas. In relation to this heterogeneity, we further
hypothesize that a multi-region approach to mitigation
such as in [57] will further lower the total cost of the optimal control strategies. Hence, though we do not include
such migratory flows and heterogeneity in our analysis,
extensions may valuably consider these factors as well.
We additionally assume that vaccines work by transitioning individuals to a removed compartment. However,
it is not the case that all vaccines guarantee 100% immunity for all individuals. Additionally, for parsimony, our
model does not incorporate a number of wide-ranging
issues which remain pressing to address, yet are beyond
the scope of this work. These include: prioritized vaccinations of various segments of the population, lesser-known
dynamics of reinfection with COVID-19, the variability in the economic cost of the controls, the impact of
emerging variants of the pathogen, documented distinctions between being protected from symptoms while
being able to transmit the virus to others, or the practical circumstances of administering vaccines requiring
multiple doses [58, 59]. With regard to this latter limitation, we specifically do not model potential logistical
impediments in vaccine scheduling or temporary states
of partial protection resulting from initial doses [60].
Such considerations therefore place caveats on the implications of our results, further highlighting the need for
robust investment in these strategies when translating
them into real-world policies. These factors may likewise
be modelled with greater precision in succeeding work as
growing knowledge continues to accumulate in line with
close monitoring by the scientific community [61].

Conclusions
This study applies optimal control theory to an epidemiological model to calculate the optimal efforts required for
precautionary measures, asymptomatic case detection,
symptomatic case detection, and vaccination to mitigate
the impact of the COVID-19 pandemic. Using parameter

Estadilla et al. Infect Dis Poverty

(2021) 10:107

values suitable to the Philippines, we show that precautionary measures and symptomatic case detection are
essential interventions to minimize infections at an efficient cost. Furthermore, relaxation of measures is feasible
after an early and maximal implementation of all controls. Our results also highlight that increasing vaccination capacity and timely acquisition of vaccines are key to
reducing the total implementation cost, leading to earlier
relaxation of the other non-pharmaceutical interventions
in the optimal strategy. This work provides a quantitative reference for drafting policies designed to control the
pandemic in the most efficient manner.
Abbreviation
COVID-19: Coronavirus disease 2019.
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